Buprenorphine is a semi-synthetic opioid analgesic derived from thebaine. It is a partial mu-opioid receptor agonist and a kappa-opioid receptor antagonist. In the 0.6mg strength, it is primarily used for the management of moderate to severe acute pain, often in sublingual tablet form. Its unique pharmacology provides effective analgesia with a ceiling effect on respiratory depression, making it safer than full agonists in certain contexts, though it remains a potent Schedule X drug in India with significant abuse potential.
Adult: For Acute Pain (Sublingual): Initial dose 0.2-0.4 mg sublingually. The 0.6mg tablet may be used for subsequent doses based on response, every 6-8 hours as needed. Titrate slowly. Usual range: 0.6mg to 1.2mg per dose. For opioid-naive patients, start at the lower end.
Note: For sublingual tablet: Place tablet under the tongue and allow it to dissolve completely. Do not chew, crush, or swallow the tablet whole. Do not eat or drink until the tablet is fully dissolved. Avoid talking during dissolution. For optimal absorption, the mouth should not be dry; a sip of water before administration can help.
Buprenorphine binds with high affinity to mu-opioid receptors (MOR) in the central nervous system, acting as a partial agonist. It produces analgesic and subjective effects but with less intrinsic activity than full agonists like morphine. It also acts as an antagonist at the kappa-opioid receptor (KOR). Its partial agonism at MOR is responsible for the ceiling effect on respiratory depression.
Pregnancy: Pregnancy Category C (US FDA). Limited human data. Not recommended during pregnancy, especially near term, due to risk of neonatal opioid withdrawal syndrome (NOWS). Use only if potential benefit justifies potential fetal risk. Can be used for medication-assisted treatment (MAT) of opioid use disorder in pregnancy under specialist care.
Driving: May impair mental and/or physical abilities required for driving or operating machinery. Patients should be cautioned not to drive or use machinery until they know how the drug affects them, especially during initiation and dose titration.
| Benzodiazepines (e.g., Alprazolam, Diazepam) | Profound sedation, respiratory depression, coma, and death. | Major - Contraindicated unless in a controlled medical setting. |
| Other CNS Depressants (Alcohol, Barbiturates, Sedative-hypnotics) | Additive CNS depression, increased risk of respiratory depression. | Major |
| CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Clarithromycin, Ritonavir) | Increased buprenorphine plasma levels, risk of toxicity. | Moderate |
| CYP3A4 Inducers (e.g., Rifampicin, Carbamazepine, Phenytoin) | Decreased buprenorphine plasma levels, reduced efficacy, potential withdrawal. | Moderate |
| Monoamine Oxidase Inhibitors (MAOIs) | Risk of serotonin syndrome and exaggerated opioid effects. | Major - Contraindicated. |
| Serotonergic Drugs (SSRIs, SNRIs, TCAs, Tramadol) | Increased risk of serotonin syndrome. | Moderate |
| Muscle Relaxants | Enhanced neuromuscular blocking action and respiratory depression. | Moderate |
| Anticholinergic Drugs | Increased risk of urinary retention and severe constipation. | Moderate |
| Full Opioid Agonists (Morphine, Fentanyl) | Buprenorphine may block the effects of full agonists or precipitate withdrawal. | Major |
Same composition (Buprenorphine (0.6mg)), different brands: